| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972007 | The Journal of Heart and Lung Transplantation | 2009 | 6 Pages |
Abstract
A 12-month CMV prophylaxis with oral valganciclovir is effective in significantly reducing CMV viremia and CMV disease/syndrome in high-risk lung transplant recipients. In addition, a reduction in acute and recurrent rejection episodes was observed, possibly due to less CMV viremia and subsequent immunomodulatory effects.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Peter MD, Barbara MD, Heidrun MD, Ali Mir MD, Maya MD, György MD, Clemens MD, Walter MD,